Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perifosine - AEterna Zentaris

Drug Profile

Perifosine - AEterna Zentaris

Alternative Names: AEZS-104; D-21266; KRX-0401; NSC-639966; Perifosin; YHI-1003

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Yakult Honsha
  • Class Antineoplastics; Quaternary ammonium compounds; Radiosensitisers; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Proto oncogene protein c-akt inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma; Gynaecological cancer
  • No development reported Neuroblastoma; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Gastrointestinal stromal tumours; Leukaemia; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In infants, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
  • 01 Jul 2017 AEterna Zentaris completes a phase I trial in Solid tumours(In adolescents, In children, In infants, In adults, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet) (NCT00776867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top